(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are LM Funding America, Meten EdtechX Education Group Ltd., and Ontrak.

The three biggest losers today are Medigus Ltd., OncoSec Medical Incorporated, and Larimar Therapeutics.

Winners today

1. LM Funding America (LMFA) – 42.47%

LM Funding America, Inc., through its subsidiary, LM Funding, LLC, operates as a specialty finance company. It provides funding to nonprofit community associations (Associations) primarily located in the state of Florida, as well as in the states of Washington, Colorado, and Illinois. The company offers funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It is also involved in the business of purchasing delinquent accounts on various terms tailored to suit each Association's financial needs, including under its New Neighbor Guaranty program. In addition, the company provides medical insurance products for international travelers. LM Funding America, Inc. was founded in 2008 and is based in Tampa, Florida.

NASDAQ ended the session with LM Funding America rising 42.47% to $1.04 on Tuesday, after two sequential sessions in a row of gains. NASDAQ slid 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, LM Funding America has a trailing twelve months EPS of $-2.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -49.88%.

Yearly Top and Bottom Value

LM Funding America’s stock is valued at $1.04 at 17:32 EST, way under its 52-week high of $1.86 and way higher than its 52-week low of $0.55.

More news about LM Funding America.

2. Meten EdtechX Education Group Ltd. (METXW) – 33%

NASDAQ ended the session with Meten EdtechX Education Group Ltd. jumping 33% to $0.04 on Tuesday, after five sequential sessions in a row of losses. NASDAQ fell 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat bearish trend trading session today.

Yearly Top and Bottom Value

Meten EdtechX Education Group Ltd.’s stock is valued at $0.04 at 17:32 EST, higher than its 52-week high of $0.04.

More news about Meten EdtechX Education Group Ltd..

3. Ontrak (OTRKP) – 13.6%

Ontrak, Inc. operates as an artificial intelligence powered, virtualized outpatient healthcare treatment company that provides in-person or telehealth intervention services to health plans and other third-party payors. Its Ontrak PRE (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends care pathways that people are willing to follow, and engages people who aren't getting the care they need. The company's technology-enabled, OnTrak, program is designed to treat health plan members with unaddressed behavioral health conditions that cause or exacerbate chronic medical diseases, such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was founded in 2003 and is headquartered in Santa Monica, California.

NASDAQ ended the session with Ontrak jumping 13.6% to $0.57 on Tuesday while NASDAQ fell 0.18% to $12,343.05.

Earnings Per Share

As for profitability, Ontrak has a trailing twelve months EPS of $-2.843.

Yearly Top and Bottom Value

Ontrak’s stock is valued at $0.57 at 17:32 EST, way below its 52-week high of $5.67 and way above its 52-week low of $0.36.

Volume

Today’s last reported volume for Ontrak is 2337 which is 73.64% below its average volume of 8866.

Moving Average

Ontrak’s value is way under its 50-day moving average of $0.64 and way under its 200-day moving average of $1.11.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Feb 13, 2022, the estimated forward annual dividend rate is 2.38 and the estimated forward annual dividend yield is 143.07%.

More news about Ontrak.

4. Mesa Air Group (MESA) – 12.67%

Mesa Air Group, Inc. operates as the holding company for Mesa Airlines, Inc. that provides regional air carrier services under capacity purchase agreements with the American Airlines and the United Airlines. As of September 30, 2020, it operated a fleet of 146 aircraft with approximately 373 daily departures to 102 cities in the United States and Mexico. The company was founded in 1982 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Mesa Air Group rising 12.67% to $1.69 on Tuesday, after two consecutive sessions in a row of gains. NASDAQ slid 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Mesa Air Group has a trailing twelve months EPS of $-4.91.

Sales Growth

Mesa Air Group’s sales growth is negative 0.2% for the present quarter and 11.7% for the next.

More news about Mesa Air Group.

5. Viking Therapeutics (VKTX) – 12.49%

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Viking Therapeutics jumping 12.49% to $24.74 on Tuesday, after two successive sessions in a row of losses. NASDAQ slid 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.71%.

Volume

Today’s last reported volume for Viking Therapeutics is 13021500 which is 180.84% above its average volume of 4636580.

Volatility

Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.53%, a positive 0.82%, and a positive 4.96%.

Viking Therapeutics’s highest amplitude of average volatility was 1.55% (last week), 3.24% (last month), and 4.96% (last quarter).

More news about Viking Therapeutics.

6. Magenta Therapeutics (MGTA) – 10.27%

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent prophylaxis of graft-versus-host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate potential utility of MGTA-117 for conditioning of patients receiving one or more investigational lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Magenta Therapeutics rising 10.27% to $0.70 on Tuesday while NASDAQ dropped 0.18% to $12,343.05.

Earnings Per Share

As for profitability, Magenta Therapeutics has a trailing twelve months EPS of $-1.15.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -54.88%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 5.1% and positive 3.4% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Magenta Therapeutics’s EBITDA is 3.46.

More news about Magenta Therapeutics.

7. Marker Therapeutics (MRKR) – 9.6%

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

NASDAQ ended the session with Marker Therapeutics rising 9.6% to $1.37 on Tuesday, following the last session’s upward trend. NASDAQ fell 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Marker Therapeutics has a trailing twelve months EPS of $-3.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -94.14%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 166.5%, now sitting on 9.01M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 33.3% and 27.3%, respectively.

Moving Average

Marker Therapeutics’s worth is above its 50-day moving average of $1.25 and way under its 200-day moving average of $2.83.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Marker Therapeutics’s EBITDA is -4.28.

More news about Marker Therapeutics.

8. Mereo BioPharma Group plc (MREO) – 8.7%

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

NASDAQ ended the session with Mereo BioPharma Group plc jumping 8.7% to $1.25 on Tuesday, following the last session’s upward trend. NASDAQ slid 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Mereo BioPharma Group plc has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.63%.

Yearly Top and Bottom Value

Mereo BioPharma Group plc’s stock is valued at $1.25 at 17:32 EST, way under its 52-week high of $1.85 and way above its 52-week low of $0.40.

More news about Mereo BioPharma Group plc.

9. aTyr Pharma (LIFE) – 8.44%

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product ATYR1923 is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

NASDAQ ended the session with aTyr Pharma rising 8.44% to $2.57 on Tuesday while NASDAQ fell 0.18% to $12,343.05.

Earnings Per Share

As for profitability, aTyr Pharma has a trailing twelve months EPS of $-1.62.

More news about aTyr Pharma.

10. Liberty Latin America Ltd. (LILAK) – 8.38%

Liberty Latin America Ltd., together with its subsidiaries, provides fixed, mobile, and subsea telecommunications services. The company offers communications and entertainment services, including video, broadband internet, fixed-line telephony, and mobile services to residential and business customers; and business products and services that include enterprise-grade connectivity, data center, hosting, and managed solutions, as well as information technology solutions for small and medium enterprises, international companies, and governmental agencies. It also operates a sub-sea and terrestrial fiber optic cable network that connects approximately 40 markets. The company provides its services in approximately 20 countries in Latin America, the Caribbean, Chile, and Costa Rica under the brands of C&W, VTR, Liberty Puerto Rico, Cabletica, BTC, UTS, Flow, and Móvil. Liberty Latin America Ltd. was incorporated in 2017 and is based in Denver, Colorado.

NASDAQ ended the session with Liberty Latin America Ltd. jumping 8.38% to $8.28 on Tuesday while NASDAQ fell 0.18% to $12,343.05.

Earnings Per Share

As for profitability, Liberty Latin America Ltd. has a trailing twelve months EPS of $-0.78.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.97%.

Volume

Today’s last reported volume for Liberty Latin America Ltd. is 1385120 which is 18.98% above its average volume of 1164100.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Liberty Latin America Ltd.’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth declined by 9.4%, now sitting on 4.7B for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Liberty Latin America Ltd.’s EBITDA is 1.88.

More news about Liberty Latin America Ltd..

Losers Today

1. Medigus Ltd. (MDGSW) – -43.37%

NASDAQ ended the session with Medigus Ltd. dropping 43.37% to $0.05 on Tuesday, after five sequential sessions in a row of losses. NASDAQ slid 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat down trend trading session today.

Yearly Top and Bottom Value

Medigus Ltd.’s stock is valued at $0.05 at 17:32 EST, way under its 52-week high of $0.08 and above its 52-week low of $0.05.

More news about Medigus Ltd..

2. OncoSec Medical Incorporated (ONCS) – -39.73%

OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.

NASDAQ ended the session with OncoSec Medical Incorporated dropping 39.73% to $0.50 on Tuesday, after two sequential sessions in a row of gains. NASDAQ slid 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, OncoSec Medical Incorporated has a trailing twelve months EPS of $-15.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -410.17%.

More news about OncoSec Medical Incorporated.

3. Larimar Therapeutics (LRMR) – -29.05%

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.

NASDAQ ended the session with Larimar Therapeutics sliding 29.05% to $3.59 on Tuesday while NASDAQ dropped 0.18% to $12,343.05.

Earnings Per Share

As for profitability, Larimar Therapeutics has a trailing twelve months EPS of $-1.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.33%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 49% and 46.8%, respectively.

Yearly Top and Bottom Value

Larimar Therapeutics’s stock is valued at $3.59 at 17:32 EST, way below its 52-week high of $6.85 and way higher than its 52-week low of $1.53.

More news about Larimar Therapeutics.

4. Tattooed Chef (TTCF) – -25.15%

Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, and plant-based burgers. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores. As of December 31, 2021, it operated approximately 14,000 retail outlets. Tattooed Chef, Inc. is headquartered in Paramount, California.

NASDAQ ended the session with Tattooed Chef sliding 25.15% to $0.61 on Tuesday while NASDAQ dropped 0.18% to $12,343.05.

Earnings Per Share

As for profitability, Tattooed Chef has a trailing twelve months EPS of $-1.07.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Tattooed Chef’s stock is considered to be overbought (>=80).

More news about Tattooed Chef.

5. Aspen Group (ASPU) – -21.99%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group falling 21.99% to $0.06 on Tuesday, following the last session’s upward trend. NASDAQ fell 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.28%.

Yearly Top and Bottom Value

Aspen Group’s stock is valued at $0.06 at 17:32 EST, way below its 52-week high of $1.34 and way higher than its 52-week low of $0.03.

Sales Growth

Aspen Group’s sales growth is negative 24% for the current quarter and negative 29.3% for the next.

Moving Average

Aspen Group’s value is way under its 50-day moving average of $0.10 and way below its 200-day moving average of $0.35.

Volume

Today’s last reported volume for Aspen Group is 40774 which is 95.07% below its average volume of 827620.

More news about Aspen Group.

6. Spectra Energy (SE) – -19.05%

Sea Limited, together with its subsidiaries, engages in the digital entertainment, e-commerce, and digital financial service businesses in Southeast Asia, Latin America, rest of Asia, and internationally. It offers Garena digital entertainment platform for users to access mobile and PC online games, as well as eSports operations. The company also operates Shopee e-commerce platform, a mobile-centric marketplace that provides integrated payment and logistics infrastructure and seller services. In addition, it offers SeaMoney digital financial services to individuals and businesses, including offline and online mobile wallet, and payment processing services, as well as other offerings across credit, insurtech, and digital bank services under the ShopeePay, SPayLater, SeaBank, SeaInsure, and other digital financial services brands; and payment processing services for Shopee. The company was formerly known as Garena Interactive Holding Limited and changed its name to Sea Limited in April 2017. Sea Limited was incorporated in 2009 and is headquartered in Singapore.

NYSE ended the session with Spectra Energy dropping 19.05% to $71.29 on Tuesday while NYSE dropped 1.26% to $15,129.25.

Earnings Per Share

As for profitability, Spectra Energy has a trailing twelve months EPS of $-2.89.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -25.05%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 137.5% and 124%, respectively.

Volume

Today’s last reported volume for Spectra Energy is 20948900 which is 333.41% above its average volume of 4833460.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.1%, now sitting on 12.45B for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Spectra Energy’s EBITDA is 70.22.

More news about Spectra Energy.

7. Horizon Therapeutics (HZNP) – -13.76%

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

NASDAQ ended the session with Horizon Therapeutics falling 13.76% to $96.80 on Tuesday while NASDAQ slid 0.18% to $12,343.05.

Earnings Per Share

As for profitability, Horizon Therapeutics has a trailing twelve months EPS of $1.59.

PE Ratio

Horizon Therapeutics has a trailing twelve months price to earnings ratio of 60.88. Meaning, the purchaser of the share is investing $60.88 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.5%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 4.7% and 14.4%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6%, now sitting on 3.58B for the twelve trailing months.

More news about Horizon Therapeutics.

8. Nephros (NEPH) – -11.49%

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.

NASDAQ ended the session with Nephros falling 11.49% to $1.25 on Tuesday while NASDAQ slid 0.18% to $12,343.05.

Earnings Per Share

As for profitability, Nephros has a trailing twelve months EPS of $-0.41.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 58.3% and 90.3%, respectively.

More news about Nephros.

9. Maxeon Solar Technologies, Ltd. (MAXN) – -10.51%

Maxeon Solar Technologies, Ltd. designs, manufactures, markets, and sells solar panels and related solar system components worldwide. The company provides interdigitated back contact and shingled solar cells and panels under the SunPower brand. It offers its products to dealers, project developers, system integrators, distributors, resellers, and residential and small-scale commercial customers. The company is headquartered in Singapore.

NASDAQ ended the session with Maxeon Solar Technologies, Ltd. falling 10.51% to $32.68 on Tuesday while NASDAQ fell 0.18% to $12,343.05.

Earnings Per Share

As for profitability, Maxeon Solar Technologies, Ltd. has a trailing twelve months EPS of $-8.53.

Moving Average

Maxeon Solar Technologies, Ltd.’s value is way higher than its 50-day moving average of $27.30 and way higher than its 200-day moving average of $21.95.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Maxeon Solar Technologies, Ltd.’s EBITDA is 1.55.

Sales Growth

Maxeon Solar Technologies, Ltd.’s sales growth is 52.6% for the current quarter and 43% for the next.

Volume

Today’s last reported volume for Maxeon Solar Technologies, Ltd. is 1860500 which is 63.29% above its average volume of 1139370.

More news about Maxeon Solar Technologies, Ltd..

10. Inovio Pharmaceuticals (INO) – -8.88%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals sliding 8.88% to $0.70 on Tuesday, following the last session’s upward trend. NASDAQ dropped 0.18% to $12,343.05, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.09.

Moving Average

Inovio Pharmaceuticals’s worth is way below its 50-day moving average of $0.91 and way under its 200-day moving average of $1.65.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Inovio Pharmaceuticals’s EBITDA is -2.58.

Volume

Today’s last reported volume for Inovio Pharmaceuticals is 8245060 which is 54.63% above its average volume of 5332030.

Yearly Top and Bottom Value

Inovio Pharmaceuticals’s stock is valued at $0.70 at 17:32 EST, way below its 52-week high of $2.82 and higher than its 52-week low of $0.69.

More news about Inovio Pharmaceuticals.

Stay up to date with our winners and losers daily report